Cargando…

Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol

INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Salinero-Fort, Miguel Ángel, de Burgos-Lunar, Carmen, Mostaza Prieto, José, Lahoz Rallo, Carlos, Abánades-Herranz, Juan Carlos, Gómez-Campelo, Paloma, Laguna Cuesta, Fernando, Estirado De Cabo, Eva, García Iglesias, Francisca, González Alegre, Teresa, Fernández Puntero, Belén, Montesano Sánchez, Luis, Vicent López, David, Cornejo Del Río, Víctor, Fernández García, Pedro J, Sabín Rodríguez, Concesa, López López, Silvia, Patrón Barandío, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521512/
https://www.ncbi.nlm.nih.gov/pubmed/26220868
http://dx.doi.org/10.1136/bmjopen-2014-007195
_version_ 1782383824473161728
author Salinero-Fort, Miguel Ángel
de Burgos-Lunar, Carmen
Mostaza Prieto, José
Lahoz Rallo, Carlos
Abánades-Herranz, Juan Carlos
Gómez-Campelo, Paloma
Laguna Cuesta, Fernando
Estirado De Cabo, Eva
García Iglesias, Francisca
González Alegre, Teresa
Fernández Puntero, Belén
Montesano Sánchez, Luis
Vicent López, David
Cornejo Del Río, Víctor
Fernández García, Pedro J
Sabín Rodríguez, Concesa
López López, Silvia
Patrón Barandío, Pedro
author_facet Salinero-Fort, Miguel Ángel
de Burgos-Lunar, Carmen
Mostaza Prieto, José
Lahoz Rallo, Carlos
Abánades-Herranz, Juan Carlos
Gómez-Campelo, Paloma
Laguna Cuesta, Fernando
Estirado De Cabo, Eva
García Iglesias, Francisca
González Alegre, Teresa
Fernández Puntero, Belén
Montesano Sánchez, Luis
Vicent López, David
Cornejo Del Río, Víctor
Fernández García, Pedro J
Sabín Rodríguez, Concesa
López López, Silvia
Patrón Barandío, Pedro
author_sort Salinero-Fort, Miguel Ángel
collection PubMed
description INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the progression of the disease and to avoid cardiovascular complications. Different scores for identifying undiagnosed diabetes have been reported, however, their performance in populations of southern Europe has not been sufficiently evaluated. The main objectives of our study are: to evaluate the screening performance and cut-off points of the main scores that identify the risk of undiagnosed T2DM and prediabetes in a Spanish population, and to develop and validate our own predictive models of undiagnosed T2DM (screening model), and future T2DM (prediction risk model) after 5-year follow-up. As a secondary objective, we will evaluate the atherosclerotic burden of the population with undiagnosed T2DM. METHODS AND ANALYSIS: Population-based prospective cohort study with baseline screening, to evaluate the performance of the FINDRISC, DANISH, DESIR, ARIC and QDScore, against the gold standard tests: Fasting plasma glucose, oral glucose tolerance and/or HbA1c. The sample size will include 1352 participants between the ages of 45 and 74 years. Analysis: sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative and receiver operating characteristic curves and area under curve. Binary logistic regression for the first 700 individuals (derivation) and last 652 (validation) will be performed. All analyses will be calculated with their 95% CI; statistical significance will be p<0.05. ETHICS AND DISSEMINATION: The study protocol has been approved by the Research Ethics Committee of the Carlos III Hospital (Madrid). The score performance and predictive model will be presented in medical conferences, workshops, seminars and round table discussions. Furthermore, the predictive model will be published in a peer-reviewed medical journal to further increase the exposure of the scores.
format Online
Article
Text
id pubmed-4521512
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45215122015-08-05 Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol Salinero-Fort, Miguel Ángel de Burgos-Lunar, Carmen Mostaza Prieto, José Lahoz Rallo, Carlos Abánades-Herranz, Juan Carlos Gómez-Campelo, Paloma Laguna Cuesta, Fernando Estirado De Cabo, Eva García Iglesias, Francisca González Alegre, Teresa Fernández Puntero, Belén Montesano Sánchez, Luis Vicent López, David Cornejo Del Río, Víctor Fernández García, Pedro J Sabín Rodríguez, Concesa López López, Silvia Patrón Barandío, Pedro BMJ Open Public Health INTRODUCTION: The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. When diagnosed, many patients already have organ damage or advance subclinical atherosclerosis. An early diagnosis could allow the implementation of lifestyle changes and treatment options aimed at delaying the progression of the disease and to avoid cardiovascular complications. Different scores for identifying undiagnosed diabetes have been reported, however, their performance in populations of southern Europe has not been sufficiently evaluated. The main objectives of our study are: to evaluate the screening performance and cut-off points of the main scores that identify the risk of undiagnosed T2DM and prediabetes in a Spanish population, and to develop and validate our own predictive models of undiagnosed T2DM (screening model), and future T2DM (prediction risk model) after 5-year follow-up. As a secondary objective, we will evaluate the atherosclerotic burden of the population with undiagnosed T2DM. METHODS AND ANALYSIS: Population-based prospective cohort study with baseline screening, to evaluate the performance of the FINDRISC, DANISH, DESIR, ARIC and QDScore, against the gold standard tests: Fasting plasma glucose, oral glucose tolerance and/or HbA1c. The sample size will include 1352 participants between the ages of 45 and 74 years. Analysis: sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative and receiver operating characteristic curves and area under curve. Binary logistic regression for the first 700 individuals (derivation) and last 652 (validation) will be performed. All analyses will be calculated with their 95% CI; statistical significance will be p<0.05. ETHICS AND DISSEMINATION: The study protocol has been approved by the Research Ethics Committee of the Carlos III Hospital (Madrid). The score performance and predictive model will be presented in medical conferences, workshops, seminars and round table discussions. Furthermore, the predictive model will be published in a peer-reviewed medical journal to further increase the exposure of the scores. BMJ Publishing Group 2015-07-28 /pmc/articles/PMC4521512/ /pubmed/26220868 http://dx.doi.org/10.1136/bmjopen-2014-007195 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Public Health
Salinero-Fort, Miguel Ángel
de Burgos-Lunar, Carmen
Mostaza Prieto, José
Lahoz Rallo, Carlos
Abánades-Herranz, Juan Carlos
Gómez-Campelo, Paloma
Laguna Cuesta, Fernando
Estirado De Cabo, Eva
García Iglesias, Francisca
González Alegre, Teresa
Fernández Puntero, Belén
Montesano Sánchez, Luis
Vicent López, David
Cornejo Del Río, Víctor
Fernández García, Pedro J
Sabín Rodríguez, Concesa
López López, Silvia
Patrón Barandío, Pedro
Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title_full Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title_fullStr Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title_full_unstemmed Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title_short Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol
title_sort validating prediction scales of type 2 diabetes mellitus in spain: the spredia-2 population-based prospective cohort study protocol
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521512/
https://www.ncbi.nlm.nih.gov/pubmed/26220868
http://dx.doi.org/10.1136/bmjopen-2014-007195
work_keys_str_mv AT salinerofortmiguelangel validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT deburgoslunarcarmen validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT mostazaprietojose validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT lahozrallocarlos validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT abanadesherranzjuancarlos validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT gomezcampelopaloma validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT lagunacuestafernando validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT estiradodecaboeva validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT garciaiglesiasfrancisca validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT gonzalezalegreteresa validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT fernandezpunterobelen validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT montesanosanchezluis validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT vicentlopezdavid validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT cornejodelriovictor validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT fernandezgarciapedroj validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT sabinrodriguezconcesa validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT lopezlopezsilvia validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT patronbarandiopedro validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol
AT validatingpredictionscalesoftype2diabetesmellitusinspainthespredia2populationbasedprospectivecohortstudyprotocol